Is CRXL a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

25 people get CRXL articles and Market Currents by email alert.

Get email alerts on CRXL »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Crucell Beefs Up R&D
The Burrill Report • Sun, Feb 14, 2010
Crucell Advances Hepatitis Vaccine in China
ChinaBio Today • Thu, Dec 11, 2008 • 1 Comment
Crucell to Break Even with $200M Vaccine Contracts
H.S. Ayoub • Mon, Dec 4, 2006

To learn more about Seeking Alpha Pro, click here.

This Biopharmaceutical Could Be Something Special
Steven Bulwa • Tue, May 8, 2012 • 9 Comments
What's Different This Time: Mergers And Takeovers
Global Investing Editor • Tue, Nov 22, 2011
Momentum Ideas: 16 Stocks Rallying on Analyst Ratings Upgrades
Kapitall • Wed, Mar 16, 2011
Apple: Optimistic Analysis Illustrates What's Wrong With Typical Investment Approach
Steven Bulwa • Mon, Jan 3, 2011 • 54 Comments
Stock Picking Is Alive and Well - Reviewing Our Best 2010 Performers
Steven Bulwa • Wed, Dec 29, 2010 • 3 Comments
10 Healthcare Stocks Seeing Institutional Buying
Kapitall • Sun, Dec 19, 2010
Cypress Rises 20 Percent on the Possibility of a Sale to Ramius: Biotech's Latest M&A Action
The Burrill Report • Sun, Dec 12, 2010
Wall Street Breakfast: Must-Know News
SA Editor Rachael Granby • Wed, Dec 8, 2010 • 22 Comments
This Market Requires Caution and Patience
Steven Bulwa • Sat, Nov 27, 2010
Irish Fallout: 25 European Stocks With Bearish Options Sentiment
Kapitall • Tue, Nov 23, 2010 • 3 Comments
Crucell Rejects Shareholder Criticism Over J&J Takeover Bid
The Burrill Report • Tue, Oct 12, 2010 • 3 Comments
Merger Arbitrage Mondays: October 11, 2010
Asif Suria • Mon, Oct 11, 2010
Wall Street Breakfast: Must-Know News
SA Editor Rachael Granby • Wed, Oct 6, 2010 • 19 Comments
Crucell Deal Will Expand J&J’s Position in Growing Vaccine Market: Biotech's Latest M&A Activity
The Burrill Report • Sun, Sep 19, 2010 • 5 Comments
Crucell Soars on Johnson & Johnson Potential Offer
Proactive Investor • Sun, Sep 19, 2010 • 3 Comments
Wall Street Breakfast: Must-Know News
SA Editor Rachael Granby • Fri, Sep 17, 2010 • 27 Comments
Smart Money's Top 9 Biotech Picks
Kapitall • Thu, Sep 16, 2010 • 2 Comments
Checking Up on Healthcare
Ockham Research • Wed, Jun 16, 2010 • 1 Comment
Hedge Fund Bridger Management Is Bullish on Healthcare
Market Folly • Sun, Feb 28, 2010 • 3 Comments
Glaxo-Intercell Deal Could Bring New Developments to Vaccine Market
EP Vantage • Fri, Dec 11, 2009

Crucell N.V. ADS Q4 2009 Earnings Call Transcript
Tue, Feb 9, 2010

J&J Recalled Products Back on Shelves This Year: CEO

at CNBC.com (Feb 17, 2011)
Biotech Stocks: Diet-drug makers in spotlight

at MarketWatch.com (Dec 8, 2010)
Stocks Pause After Rally to Close Mixed

at CNBC.com (Oct 6, 2010)
Stocks Turn Mixed Ahead of Close; Techs Fall

at CNBC.com (Oct 6, 2010)
Buy Stocks Ahead of Earnings: Managing Director

at CNBC.com (Oct 6, 2010)
Indications: U.S. stock futures turn lower after ADP data

at MarketWatch.com (Oct 6, 2010)
Market Snapshot: U.S. stocks to try for fourth week of gains

at MarketWatch.com (Sep 17, 2010)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 17, 2010)
Biotech Stocks: Crucell, Arena sharpest movers in drug sector

at MarketWatch.com (Sep 17, 2010)
Johnson & Johnson in talks to buy Crucell

at MarketWatch.com (Sep 17, 2010)
Europe Markets: Europe stocks end lower on Ireland fears

at MarketWatch.com (Sep 17, 2010)

CRXL vs. ETF Alternatives

Company Description

Currently, there's no company description for CRXL.

Sector: Healthcare

Industry: Biotechnology

Country: Netherlands

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, July 17, 2012, 8:12 AM More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special items of $2.2B, comprising a write-down related to J&J's Crucell (CRXL) vaccine ops, provision for litigation, costs connected to Synthes acquisition. Cuts 2012 EPS outlook to $5.00-$5.07 from up to $5.17. Consensus is $5.14. Shares -1.4%. (PR) Comment! [Earnings, Top Stories, Healthcare]
Friday, December 10, 2010, 11:44 AM Crucell (CRXL) CEO Robert Brus works to put down a rebellion by big shareholders - including 10% holder Van Herk Groep - saying that accepting a €1.75B bid from Johnson & Johnson (JNJ) means funded research and preserving the company's identity as a vaccines center within JNJ. Opponents say €24.75/share is too low and the product pipeline will yield strong results over five to eight years. Comment!
Wednesday, December 8, 2010, 8:02 AM J&J (JNJ) formally launches its €1.75B ($2.3B) bid for Crucell (CRXL), despite objections from some of Crucell's shareholders. J&J wants control of Crucell's vaccine pipeline at a time when vaccine sales are outstripping those of prescription drugs and face less competition from generics. (previously) Comment!
Wednesday, October 6, 2010, 7:31 AM J&J (JNJ) and Crucell (CRXL +0.75%) agree to move forward with J&J's ~€1.75B offer for the shares of the Dutch biotech firm it doesn't already own, despite some shareholder objections. J&J will get control of Crucell's vaccine pipeline at a time when vaccine sales are outstripping those of prescription drugs and face less competition from generics. Comment!
Friday, September 17, 2010, 9:00 AM Premarket gainers: CRXL +55%. CBLI +17%. ALKS +5%. ORCL +4%. RIMM +4%.
Losers: ARNA -45%. OREX -8%. VVUS -5%. ERIC -5%. IRE -4%. RBY -4%. 1 Comment
Friday, September 17, 2010, 7:31 AM J&J (JNJ) is in advanced talks to buy the shares of Crucell (CRXL) it doesn't already own for around €1.75B ($2.3B) in cash, or €24.75/share. The offer is a 58% premium to Crucell's closing price yesterday in Amsterdam. Premarket: CRXL +54%. (PR) Comment!
Wednesday, May 6, 2009, 9:00 AM Premarket gainers: APAC +38%. ARM +23%. CKSW +22%. ACOR +21%. CROX +17%. AIB +17%. CTIC +16%. SUMT +17%. FIG +14%. LNC +14%. BEE +13%. ABK +11%. DAN +11%. PLT +11%. BYD +11%. HOV +9%. SRZ +9%. GNW +10%. ANR +8%. DIS +7%. CLF +7%. KFN +7%. BZH +7%. BAC +7%. HBC +6%. FITB +6%. BRCD +6%. BX +6%. DRYS +6%. HIG +5%. WFC +5%. EXM +5%. HMY +5%. ALU +5%. MGM +5%. COF +5%. AU +5%. CRXL +5%. GFI +5%. GERN +5%. Comment!
Monday, April 27, 2009, 9:02 AM Premarket gainers on swine-flu speculation: NVAX +133%. SVA +63%. BCRX +58%. AVII +35%. VICL +32%. QDEL +26%. HGSI +19%. RAD +15%. CRXL +7%. BLUD +7%. HUM +6%. BAX +4%. GSK +4%. THC +4%. GILD +4%. 1 Comment
Thursday, February 19, 2009, 9:03 AM Premarket losers: BRMN -19%. EXPE -14%. LDK -8%. CCJ -8%. BNI -4%. CRXL -4%. SHPGY -4%. HPQ -3%. Comment!
Tuesday, February 17, 2009, 9:00 AM Premarket losers: lyg -21%. MTG -17%. AEE -16%. AEG -15%. MTL -13%. DB -13%. ING -13%. MT -11%. FAS -11%. BHP -10%. IBN -10%. BAC -9%. RBS -9%. MGM -8%. DAI -8%. AAUK -8%. PHG -8%. CS -8%. CRXL -8%. WFC -8%. LVS -7%. UBS -7%. HBC -7%. WFT -7%. GM -7%. AMAG -7%. ABB -7%. STI -7%. DE -7%. Comment!
Monday, February 2, 2009, 10:46 AM Sanofi-aventis's (SNY) new CEO Chris Viehbacher says he's a buyer, and has held talks with bankers regarding funding. Possible targets include Bristol-Myers (BMY), Amgen (AMGN), Biogen Idec (BIIB) and Crucell (CRXL). Comment!
Monday, January 26, 2009, 9:00 AM Premarket losers: ROH -16%. CRXL -15%. CAT -7%. TEX -7%. DE -5%. PFE -4%. KMB -3%. FCX -3%. Comment!
Friday, January 23, 2009, 9:01 AM Premarket losers: HOG -19%. BCS -19%. COF -14%. CRXL -12%. ING -11%. DRYS -10%. MT -10%. HBAN -10%. JASO -10%. FITB -9%. RBS -8%. WFR -8%. BAC -8%. JBLU -8%. SAP -7%. PHG -7%. JPM -6%. UBS -6%. SI -6%. BP -6%. USB -6%. RTP -6%. ABB -6%. WFC -6%. BHP -6%. AAUK -6%. ASML -6%. RF -6%. Comment!
Thursday, January 8, 2009, 9:00 AM Premarket gainers: SWIM +40%. SHLD +11.5%. WFMI +8.5%. GME +7.5%. CRXL +7%. BLUD +6%. URBN +6%. ARO +4.5%. HMY +4%. GFI +4%. EMC +4%. SYT +4%. GG +4%. Comment!
Thursday, January 8, 2009, 7:26 AM Wyeth (WYE) is in talks to buy Dutch vaccine maker Crucell (CRXL), part of its efforts to gain market share in one of the fastest growing parts of the industry. Sources say a deal valuing Crucell at over €1B ($1.35B) could be reached as early as next week. Comment!

Steven Bulwa
Impressed with $PLX approval, very interesting technology with broad applications. Reminds me of $CRXL. May dip a toe in after hours.
5/1/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: I agree with PLX, but IBIO looks like a more valuable and efficient better play
5/1/12
• !Report Abuse
Steven Bulwa: $IBIO intrigues but there is something about an approved drug and $PFE in your corner that appeals to me more. Good luck.
5/1/12
• !Report Abuse
Add a reply...

140 characters

Asif Suria
J&J Launches Public Offer for Crucell Shares $JNJ $CRXL
12/8/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Mays Report
J.&J.(JNJ) Bids $2.3 Billion for Crucell (CRXL).
12/8/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Smart-Ticker.com
Last hour bears $NUVA,$DRC,$AMAG,$QSII,$PWER,$OCLR,$CRXL,$GNW,$WMGI,$NVTL...more http://s-t.cc
10/29/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Steven Bulwa
Impressed with $PLX approval, very interesting technology with broad applications. Reminds me of $CRXL. May dip a toe in after hours.
5/1/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: I agree with PLX, but IBIO looks like a more valuable and efficient better play
5/1/12
• !Report Abuse
Steven Bulwa: $IBIO intrigues but there is something about an approved drug and $PFE in your corner that appeals to me more. Good luck.
5/1/12
• !Report Abuse
Add a reply...

140 characters

CRXL Crucell NV

CRXL

Crucell NV